As volatility returns to European markets, investors are turning to dividend-paying stocks for income and stability. We examine three companies with compelling, yet distinct, dividend profiles for income-focused portfolios.
Axos Financial Inc. (AX) reported robust second-quarter earnings for fiscal 2026, highlighted by a 23.3% surge in earnings per share and significant loan portfolio expansion, even as it manages industry-wide margin pressures and rising operational costs.
Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
With economic crosswinds buffeting regional markets, income-focused investors are increasingly looking to dividend-paying equities in Asia to anchor their portfolios. We examine three prominent names offering compelling yields.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
The technology-focused lender reported solid 2025 earnings, highlighted accelerating deposit inflows and a strategic shift away from its legacy SBA portfolio. Management forecasts continued growth for 2026, banking on its digital offerings and a key securitization success.
Klarna Group confronts a wave of class action lawsuits alleging it downplayed rising loan loss risks in its buy-now-pay-later portfolio ahead of its 2025 NYSE debut. The legal challenges cast a shadow over the fintech's post-IPO performance and have sparked a broader debate about transparency in the rapidly growing BNPL sector.
A significant divestment from a short-duration bond ETF highlights a broader portfolio pivot towards growth assets as opportunity costs rise, questioning the role of capital preservation funds in a changing rate environment.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
Natural gas futures tumbled over 25% on Monday, hitting a three-week low, as a swift recovery in U.S. production and a warmer weather forecast alleviated supply concerns sparked by last week's Arctic blast.
U.S.-listed exchange-traded funds attracted $165.4 billion in January, with a notable pivot toward international stock funds as they continue to outperform domestic markets.
As Palantir Technologies prepares to report Q4 results, soaring demand for its AI platform collides with sky-high valuations, leaving investors to weigh robust growth against bubble fears.
Morgan Stanley's top strategist argues that recent U.S. trade shifts have prompted nations worldwide to reassess and leverage their own economic strengths, creating a multi-year investment opportunity in a more multipolar global order.
Investment firm Monument Capital Management has completely exited its position in Grand Canyon Education, selling 19,133 shares. The move comes as the education services provider navigates legal challenges and market underperformance.
A powerful but uncommon shift in market leadership is underway as small-caps, energy, and value stocks drive gains. While a sign of health, historical parallels to similar 'breadth' events often coincided with economic stress.
The CoinDesk 20 Index, a key benchmark for the digital asset market, fell sharply over the weekend, with every constituent in the red. Ethereum's 13.9% drop was a primary driver of the downturn.
After a prolonged period of U.S. dominance, international equities are staging a comeback. Analysts point to shifting fundamentals, attractive valuations, and a weakening dollar as tailwinds for emerging markets, with one Vanguard ETF positioned at the center of this transition.
Investor appetite for hedge funds hits a record high, with quantitative and discretionary macro strategies leading demand. New data reveals these approaches captured over 70% of industry inflows last year, as allocators seek diversification and uncorrelated returns.
Defense contractor L3Harris Technologies wins a significant U.S. Navy award to develop the Red Wolf long-range precision strike vehicle for the Marine Corps, underscoring the Pentagon's focus on advanced targeting capabilities and bolstering the company's portfolio in next-generation weapons.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
